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Osteolytic bone disease (OBD) is a frequent complication of multiple cancers, such as multiple 
myeloma. OBD is due to the disruption of balanced bone remodelling, with higher bone 
resorption due to increased osteoclast activation and osteoblast inhibition. Lectin-glycoprotein 
interactions have been implicated in osteoclast formation. In the current study, we set out to 
identify lectins that are involved in osteoclastogenesis and to study their role in this process. 
We anticipate that this research will lead to the identification of new targets for the treatment 
of OBD.  
Gene Set Enrichment Analysis on publically available microarray data showed a lower 
expression of galectin-1 (gal-1) in mature osteoclasts compared to monocytic progenitor cells. 
Gal-1 is a β-galactoside binding protein implicated in myeloma and interestingly already 
implicated in trophoblast and myoblast fusion. We confirmed a decrease of gal-1 expression 
during osteoclast formation on the RNA and protein level on primary and cell line-derived 
osteoclast cultures. Gal-1 localization by confocal microscopy was found to be predominantly 
membranous in mature osteoclasts while it was ubiquitous in progenitor cells. siRNA-mediated 
silencing of gal-1 resulted in an increased osteoclastogenesis and larger osteoclasts. Treatment 
of osteoclast cultures by Anginex, an anti-angiogenic synthetic peptide that targets gal-1, 
resulted in a reduced osteoclast formation. We observed no difference in osteoclast number in 
primary cultures derived from gal-1-/- mice compared to wild-type controls. However, gal-1-/- 
osteoclasts showed a higher resorption activity, corroborated by a higher expression and 
secretion of tartrate resistant acid phosphatase in these cultures.  
Taken together, our data implicate gal-1 in osteoclast biology. Analyses of bone parameters by 
µCT and immunohistomorphometry in gal-1-/- and wildtype mice are currently ongoing. In 
addition, gain-of-function studies and analysis of signalling pathways in osteoclasts will be 
performed. Finally, the role of gal-1 in OBD will be studied in the 5TGM.1 murine multiple 
myeloma model. 
